---
layout: default
title: Activated Charcoal Arsenic Trioxide Atropa Bellado
parent: 僅模型預測 (L5)
nav_order: 210
evidence_level: L5
indication_count: 0
---

# Activated Charcoal Arsenic Trioxide Atropa Bellado
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Ingredient Homeopathic Complex: Assessment Not Possible — Insufficient Data

## One-Sentence Summary

This candidate is a ten-ingredient complex comprising activated charcoal, arsenic trioxide, belladonna, and seven additional botanical/mineral constituents, which is not currently authorised in the United States.
The TxGNN model returned **no predicted new indications** for this submission, and the regulatory query likewise retrieved **no approved licences**.
Consequently, a standard repurposing evaluation cannot be completed at this time; a **Hold** decision is warranted until foundational data are obtained.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available — no approved licences on record |
| Predicted New Indication | None — TxGNN returned no candidates |
| TxGNN Prediction Score | N/A |
| Evidence Level | Below L5 (no predictions, no studies identified) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN prediction was generated for this submission, so this section cannot be completed in the standard manner. The following contextual note is provided instead.

The submitted "drug" string is a semicolon-delimited list of ten distinct substances — activated charcoal, arsenic trioxide, *Atropa belladonna*, *Chelidonium majus*, *Lycopodium clavatum* spore, *Matricaria chamomilla*, *Scrophularia nodosa*, *Semecarpus anacardium* juice, silver nitrate, and *Strychnos nux-vomica* seed. This profile is characteristic of a **multi-ingredient homeopathic or Ayurvedic combination**, not a single-entity pharmaceutical.

The TxGNN knowledge graph operates on individual DrugBank-mapped entities. Because no single DrugBank ID could be assigned to this multi-component string, the prediction pipeline had no entry point, and therefore produced no output. Until the submission is decomposed into individual active pharmaceutical ingredients (APIs) and each is mapped to a valid DrugBank node, repurposing scoring is technically infeasible.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for this multi-ingredient combination as a unified entity.

---

## Literature Evidence

Currently no related literature available for this multi-ingredient combination as a unified entity.

---

## US Market Information

No approved US licences (NDAs or BLAs) are on record for this combination.

---

## Safety Considerations

Several constituents in this combination carry **significant intrinsic toxicity** that warrants attention regardless of data gaps:

- **Arsenic trioxide** is a known human carcinogen and carries a US FDA Boxed Warning for QTc prolongation, electrolyte abnormalities, and differentiation syndrome.
- **Strychnos nux-vomica** seed contains strychnine, a potent convulsant with a narrow therapeutic index.
- **Atropa belladonna** contains atropine and scopolamine; anticholinergic toxidrome is a recognised risk.
- **Silver nitrate** is caustic at concentrations used medicinally.

Combination safety profiling — including drug–drug interaction (DDI) assessment among these ten ingredients — has not been performed and represents a blocking gap before any clinical evaluation.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN pipeline requires a single, DrugBank-mapped entity as input; this submission supplied a ten-ingredient string that the system could not resolve to any prediction. Without a prediction, there is no repurposing hypothesis to evaluate, and no clinical or literature evidence was retrieved to support one independently.

**To proceed, the following is needed:**

1. **Decompose the combination** — identify whether this is a recognised fixed-dose combination with a single brand name, or separate APIs that should each be submitted individually.
2. **Obtain DrugBank IDs** — map each ingredient to its DrugBank entry so that TxGNN can generate per-component predictions.
3. **Clarify the intended indication** — without a known original indication, it is impossible to anchor the "from → to" repurposing hypothesis.
4. **Safety baseline** — retrieve full package-insert warnings, contraindications, and DDI data for each constituent, particularly for arsenic trioxide and nux-vomica, before any clinical feasibility discussion.
5. **Re-run the pipeline** — once individual APIs are mapped, re-submit each to TxGNN and merge results at the combination level if appropriate.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

